Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma

JCO Oncol Pract. 2020 Aug;16(8):e751-e757. doi: 10.1200/JOP.19.00517. Epub 2020 Apr 2.

Abstract

Purpose: We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG).

Methods: We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM.

Results: GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw.

Conclusion: Our study has important implications in the care of MM, particularly in countries/areas with limited resources.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost of Illness
  • Humans
  • Multiple Myeloma* / diagnosis
  • Multiple Myeloma* / therapy
  • Point-of-Care Testing
  • Retrospective Studies